Explore chapters and articles related to this topic
A patent review of MALT1 inhibitors (2013-present)
Published in Expert Opinion on Therapeutic Patents, 2021
Isabel Hamp, Thomas J. O’Neill, Oliver Plettenburg, Daniel Krappmann
In another approach, Toray described a series of diphenyl pyrazole guanidine derivatives (Figure 9, compounds 43 and
44) (WO2017/057695) [97]. The initial application is complemented by the two other patent applications WO2018/021520 and WO2018/159650 [98,99], utilizing pyridine or phenyl groups as central scaffolds. One recent publication by Toray scientists describes the MALT1 inhibitory properties of a series of basic diphenyl pyrazoles, and the most potent compound displays potency in the range of thioridazine and mepazine (Figure 9, compound 45) [70,100]. Of note, the Toray compounds share some structural similarities to MI-2 (Figure 4, compound 1), but they are not reactive. The publication suggested that these substances inhibit MALT1 through binding to the allosteric pocket, which may question if the MI-2 mode of action on MALT1 is exclusively mediated via the active site [62].